Author Archives: Danzig

ADA’s 30th anniversary marks progress for disabled Americans, but there’s still work to be done – Omaha World-Herald

Posted on by

Finding a job is also an issue. Rodgers went back to college and got certified to work on computers, but he says potential employers dont want to be liable for his medical issues.

I cant get any companies to hire me, mainly because of my health, he said. That needs to be addressed.

Warner noted that many disabled individuals also worry about taking a full-time job because that can mean losing public benefits such as health insurance or Social Security payments.

Im glad for what we do have, as far as being able to be out in the community and gain access to commerce, but I do believe there are further steps that could be taken, Warner said.

Improving work opportunities for the disabled has been a focus for Harkin since he retired from the Senate in 2015. He has urged companies to overhaul training programs and do whatever else is necessary to increase their hiring of disabled Americans.

Congress could help by passing legislation that would address the issue of disabled individuals losing benefits if they find full-time employment, he said.

Sen. Tom Harkin participated in events this week marking the 30th anniversary of the ADA, including a plane ride on Friday. The first armless pilot, Jessica Cox shown with him in the plane was at the controls.

Of the various ADA anniversary events Harkin joined this week, he said the most fun was a plane ride Friday with the first armless pilot, Jessica Cox, at the controls.

The two met through her advocacy work on the United Nations Convention on the Rights of Persons with Disabilities treaty, which they both continue to push.

More here:

ADA's 30th anniversary marks progress for disabled Americans, but there's still work to be done - Omaha World-Herald

Progress still hampered by battles on the fringes – McMinnville News-Register

Posted on by

Wednesday night, Portland Mayor Ted Wheeler, also the citys police commissioner, was simultaneously being gassed by federal agents and berated by protesters cursing his name, labeling his appearance at the 56th night of protest nothing more than a photo opportunity.

The videos of federal agents dispatched by the president gassing moms and clubbing veterans simply wanting to hold a conversation are abhorrent. While the agents have legal standing to protect the federal courthouse, the tactics administered have rightfully sparked a national outcry against a militarized federal government engaging in street clashes against its citizens. It is indeed a radical response from the U.S. Executive Branch, and likely more about politics than law and order as an election nears.

But its also not a surprising occurrence in Portland, where fringe activists have historically been allowed too much leeway to ruin the pure demonstrations for First Amendment rights amid honest attempts at progress.

To quote from a 2017 editorial in this newspaper:

Whether its Republicans on the right or Democrats on the left, allowing the most radical elements of their bases to compromise their principles and mute their voices is repugnant. It helps tighten the grip of raw partisanship, thus serving to thwart reasonable policy initiatives. ...

But when black-masked anarchists infiltrated the otherwise peaceful Portland demonstrations to pelt police, set blazes, smash windows, snarl traffic and engage in random acts of mayhem, organizers were more critical of the police for restoring order than the anarchists for disrupting it. ...

The anarchists were aided and abetted by then-Mayor Charlie Hales, who established a virtually unmatched record of ineptitude during his mercifully brief tenure. They got another boost when the district attorneys office dismissed charges against virtually all the 113 arrested.

Mayoral successor Ted Wheeler, displaying an equal lack of fortitude, allowed the anarchist fringe to bring city council meetings to a grinding halt for weeks with ceaseless demands for the police chiefs ouster. And it took nothing more than an anonymous threat for Portland anarchists to force cancellation of this years 82nd Avenue of Roses Parade.

It should have come as no surprise when anarchists began tossing Molotov cocktails, setting bonfires, defacing storefronts, shattering windows and pelting police again during the union movements annual May Day Parade, staged May 1 in Portland. After all, they openly recruited participants on social media sites.

But the response from the self-proclaimed voice of the American worker was, distressingly, a condemnation of the police rather than the bomb-throwers who spoiled the party and soiled the cause.

Those following the 50-plus days of protests in Portland this summer know they have been mostly peaceful and lawful. The righteous indignation of systematic racism and police brutality is warranted and deserving of cognitive discourse leading to legislation.

But the ongoing inability or unwillingness on both sides to filter extremist views has lead to a fictitious narrative, to the point where all cops are bastards and hundreds of moms wearing yellow are nothing more than Antifa in a new outfit.

With a subsection of protesters and a president eager to fan the flames of the ongoing urban warfare, as Wheeler described what he felt Wednesday night, it is difficult to find hope in positive reconciliation. But find hope, we must.

Read the rest here:

Progress still hampered by battles on the fringes - McMinnville News-Register

Forward progress stopped on Topsy Fire – The Record-Courier

Posted on by

As of 6 p.m. forward progress on a 25-30-acre fire burning between homes and watershed on Topsy Lane.

Set by lightning around 4 p.m. the fire resulted in Topsy Lane east of Highway 395 being closed.

Firefighters say two outbuildings have been lost with damage to one home.

Smoke reduced visibility on Highway 395 for the evening commute.

1E8BF949-1874-45E9-9DB2-49623D449352

1431A6B2-6173-4DE3-9B71-F9E6CCFF3584

A1BD1E35-6FE8-464C-84F4-7BF143337641

8DB1462A-3296-4130-B77B-22F89F4933CC

14A03752-5CA1-4206-8AC0-8F95E522F07B

69334209-25C0-4E4C-95DF-2CC031D4D6C0

6C954552-69B4-491E-BA9F-8ACC9FDC268F

97DB675A-0C72-4D14-A713-A178BE52D7DD

C4C285D1-CDF4-4413-AECB-74F040B5CC2C

Show CaptionsHide Captions

East Fork Fire and Carson City Fire Department were called Thursday afternoon about 4:05 p.m. The fire was reported to be ready to jump Topsy Lane at 4:20 p.m.

Multiple fire engines and brush units are responding , structures are currently threatened.

Previous stories

At 3:36 p.m., Doppler radar was tracking a strong thunderstorm near Gardnerville.

This storm was nearly stationary, according to the National Weather Service.

Heavy rain with water covering usually dry stream beds and winds in excess of 40 mph will be possible with this storm.

At 3:36 p.m., Doppler radar was tracking a strong thunderstorm near Gardnerville.

This storm was nearly stationary, according to the National Weather Service.

Heavy rain with water covering usually dry stream beds and winds in excess of 40 mph will be possible with this storm.

Locations impacted include Johnson Lane and the Fish Springs area.

Excerpt from:

Forward progress stopped on Topsy Fire - The Record-Courier

Opinion: The secrets behind longevity HS Insider – Los Angeles Times

Posted on by

Throughout history, longevity and eternal life have been the ultimate goal of humanity. From the king of the ancient Chinese Qin dynasty to the European alchemists during the medieval age, countless people have devoted their lives to unveil the secrets of immortality.

Although none of such efforts have been proven to grant eternal life, nowadays, modern scientists succeeded to elongate the lifespan of simple organisms, such as worms and flies, by a considerable amount with meticulous manipulation of our genes. Among many of those studies, there have been three main methods that held their significance even in the human body.

Enzyme regulation

Most notably, the Scripps Research team discovered that the disruption of enzymatic pathways by small molecules can affect the lifespan of an organism. The team used Caenorhabditis elegans, a type of a roundworm, to test their hypothesis.

According to Benjamin Cravatt, Gilula Chair of Chemical Biology at Scripps Research, C.elegans worms were used for their experiment due to their relatively short lifespans (typically lives only a few weeks). Cravatts research involved about 100 compounds that were known to inhibit serine hydrolases in mammals.

In his experiment, Cravatt used each of the 100 molecules to block the enzymatic pathway and observed their effects on the lifespan of the C.elegans. When the team treated the worms that were 1 day into adulthood with the inhibiting compounds, they found that some of the compounds extended the average lifespan of the worm by at least 15%, according to Alice Chen, a graduate student in the Cravatt lab.

Chen elaborated that among the compounds, a carbamate compound called JZL 184, even extended the lifespan by 45% when treated at the optimal dose. Through further analysis, the team concluded that JZL 184 extended the worms lifespan by inhibiting fatty acid amide hydrolase 4(FAAH-4), which is known to break down a molecule called 2-AG, a molecule linked to aging in mammals.

Whats fascinating about this finding is that monoacylglycerol lipase was not present in C.elegans worms. MAGL usually breaks down the 2-AG molecules in mammals, but in the case of Chens experiment, FAAH-4 substituted the role of MAGL.

While the findings only apply to C.elegans worms as of now, the team stated that the FAAH-4 and 2-AG pathways will suggest a new path in extending human life.

Calorie Regulation

In addition, a research team led by David Sinclair, assistant professor of pathology at HMS, found that calorie regulation extends the lifespan of yeast cells. According to Sinclair, the PNC1 protein regulates a vitamin called nicotinamide, which is an inhibitor of the Sir2 molecule. Sinclair further hypothesized that since Sir2 typically extends the lifespan of yeast cells by stabilizing the ribosomal DNA, the regulation of nicotinamide, which is its inhibitor, will consequently prolong the organisms lifespan.

While the team believed that such a regulation process was initiated by the severe calorie restriction in yeast cells, they later discovered that calorie restriction had no impact on the Sir2 level. Thus, Sinclairs team tested the effect of the molecule NAD on PNC1 levels to confirm that NAD was responsible for altering the Sir2 level. It turned out: NAD had no effect on the PNC1 level.

Undeterred, with more in-depth analysis, the team finally reached the conclusion that nicotinamide, which is one of the products of the reaction between Sir2 and NAD, was responsible for the change in Sir2 level. Based on the correlation they found between Sir2 level and nicotinamide facilitated by calorie restriction, Sinclairs team is now investigating human genes that play the same role as PNC1, according to Harvard Medical School.

Mifepristone

Finally, the research team led by John Tower, professor of biological sciences at the University of Southern California, found that the drug mifepristone extends the lives of female flies that have mated.

Before the experiment, Tower had set a premise that the sex peptide in female flies from male flies reduces the lifespan of the female flies as it causes inflammation. In his study, he and his colleagues discovered that the drug mifepristone, also called RU-486, blocked the effects of the sex peptide during reproduction, which retained the female flies health and thus extended their lifespan.

What played the most significant role in the reaction was, according to Tower, a molecule called the Juvenile hormone.

According to Towers research team, the juvenile hormone is responsible for the growth and development of fruit flies throughout their life. The sex peptide, they elaborated, boosts the effect of the juvenile hormone, which causes harmful inflammation in the flies body and enervates the male flies by shifting the metabolic pathways.

Therefore, the inhibition of the sex peptide by mifepristone also regulates the level of juvenile hormone, consequently extending the lifespan of the flies. With their further testing of the drug on C.elegans, which has similar genes as those of humans, Tower suggested that their findings may be applicable to extending the lives of humans.

The life-extending technology is still in its burgeoning stage, as it only applies to simple organisms, such as worms and flies. However, while eternal life still seems improbable, humanity will proceed one step further to unveiling the secrets of longevity with scientists perpetual efforts.

Read more:

Opinion: The secrets behind longevity HS Insider - Los Angeles Times

Air Force awards contracts to develop Skyborg combat drones that ‘learn’ how to fight – Stars and Stripes

Posted on by

Four companies have been chosen to develop combat drones that will use artificial intelligence to either fully execute or support manned aircraft on strenuous or dangerous missions, the Air Force said.

Boeing, Northrop Grumman, General Atomics and Kratos Unmanned Aerial Systems were awarded contracts in support of the Air Forces Skyborg Vanguard Program, the Air Force Life Cycle Management Center said in a statement Thursday. The companies will compete for up to $400 million in orders, it said.

The program name evokes the cyborg man-machine hybrids of science fiction, but also perhaps the fictional artificial intelligence network Skynet in the Terminator film series.

Will Roper, the Air Forces assistant secretary for acquisition, technology and logistics, suggested a more endearing fictional creation, Defense News reported. At a conference last year, he likened it to the beep-booping droid R2-D2 of the Star Wars universe that helps Luke Skywalker and his father pilot their fighter spacecraft.

The real-world drones are supposed to include AI upgrades to allow them to learn how to engage enemy defense systems, as well as to share data with manned F-35 and F-15 fighters. This would allow the drones to operate in tandem with the jets in a wingman role, officials said.

Because autonomous systems can support missions that are too strenuous or dangerous for manned crews, Skyborg can increase capability significantly and be a force multiplier, Brig. Gen. Dale White, program executive officer for fighters and advanced aircraft, said in the statement. We have the opportunity to transform our warfighting capabilities and change the way we fight and employ air power.

The new drones, which will eventually replace the MQ-9 Reaper, will be designed to be attritable, meaning they will be inexpensive enough that losing one in combat would be tolerable.

The first Skyborg drones are expected to be operational by 2023. At least two models a ground attack and an air superiority version are expected to be fielded, according to Aviation Week & Space Technology.

The U.S. is not the only country developing stealthy combat drones, although its not clear whether any others are AI-enabled.

In October, China featured a prototype of the GJ-11 Sharp Sword drone at its national day parade. Russia, meanwhile, has released video of a much larger Sukhoi Su-70 drone flying in formation with an Su-35 fighter, indicating that the two are capable of operating in tandem.

And Israel has already used in Syria a stealth loitering drone that can crash into targets if its detected, or return to base if the strike is called off.

lekic.slobodan@stripes.com

A Skyborg conceptual design for a low-cost, unmanned combat drone. Four companies have been picked to build the Air Force's Skyborg drone, the Air Force Life Cycle Management Center said in a statement on July 23, 2020.AIR FORCE RESEARCH LABORATORY

article continues below

See the original post:

Air Force awards contracts to develop Skyborg combat drones that 'learn' how to fight - Stars and Stripes

The Knicks are reportedly hiring Tom Thibodeau and Knicks Twitter lost it – For The Win

Posted on by

Theres always some sort of drama or controversy with the New York Knicks and their fans. If its not one thing, its the other.

On Saturday, it was their coaching hire. The Knicks are moving forward to make former Bulls and Timberwolves head coach Tom Thibodeau their next head coach, according to a report from ESPNs Adrian Wojnarowski.

The two sides are in the middle of hammering out the final details on a contract that would keep Thibodeau in New York for the next five years. It will be on him to shape the prime of R.J. Barrett and Mitchell Robinsons careers.

You can already hear the sound of creaking knees in the background just reading that tweet.

The Knicks are in a unique space. Theyve got a ton of young talent on that team starting with Barrett and Robinson. They needed a coach who could help bring out their best while also shaping their future.

And Thibodeau definitely has one part of that down. Lets, uh, leave the Timberwolves aside for a sec. He coached Derrick Rose to an MVP season, turned Jimmy Butler and Luol Deng into All-Stars and turned Joakim Noah into a Defensive Player of the Year.

On the other hand? He ran also ran pretty much all of them into the ground Jimmy Butler is an exception because hes a cyborg.

Thibodeau is known to grind his players away with heavy minutes and that concerns a lot of Knicks fans.

The jokes were pretty funny, though.

Its all good, Knicks fans. There are a couple of silver linings, at least! First, at least its not Jason Kidd. Second, we get to use this Vine again!

Ah, yes. Everything comes full circle. Finally.

Go here to see the original:

The Knicks are reportedly hiring Tom Thibodeau and Knicks Twitter lost it - For The Win

Prepare for four more years of the most disruptive president ever – MSN Money

Posted on by

Getty Images Prepare for four more years of the most disruptive president ever

You would be hard-pressed to find anyone who doesn't harbor incredibly strong feelings about President Trump. Millions of Americans hate him. Millions still support him. "I don't have an opinion about Trump" is not something you'd expect to hear in a casual or political discussion - which is precisely the point.

For decades, Trump has been a lightning rod attracting the electrical discharges of hate and admiration with little neutral voltage in between. After he beat Hillary Clinton in 2016, he began to get zapped by hundreds of thousands of opinionated charges, and then literally millions, emanating from around the globe.

Today we could say these charges have become "matter versus antimatter," creating a dangerous energy field that may not be able to be shut down regardless of the outcome of November's presidential election.

In a speech at the American Enterprise Institute's annual dinner last year, Nikki Haley, a former U.N. ambassador and former South Carolina governor who is still a powerful voice in the GOP, cut to the chase regarding Trump: "President Trump is a disruptor. That makes some people very happy, and it makes some people very mad." She is correct - the president is a disruptor, and the need to disrupt likely is in his DNA. Our nation and the world haven't experienced another president like him.

Forget "The Art of the Deal," the book that introduced many Americans to Trump. For the past five decades, he has used "the art of disruption" to break down seemingly insurmountable walls to achieve his goals. Many times, he succeeded. Sometimes, the bricks and mortar collapsed upon him.

But even when they caved, he crawled out, dusted himself off and went about disrupting the next obstacle in his path. Those who have come to hate Trump must think they are watching a never-ending, real-life version of the "The Terminator," with Trump playing the role of the unstoppable cyborg.

Since Haley made her remarks last November, the world has been turned on its head by a deadly pandemic and our nation has been disrupted by legitimate protests and civil unrest tinged with troubling violence.

But through it all, Trump remains virtually the same. What you see is what you get. He's still that one-man disruptive force of often epic proportions. He goes full speed ahead - damn the (rhetorical) torpedoes!

Most media appear to be left of center in the U.S. and many other countries. They've come to truly loathe Trump and made their low opinions of him abundantly clear. Some world leaders and their staff have scoffed at the president too. Trump the disruptor, marching to his own beat, truly rubs them the wrong way. They want him gone.

On the other hand, the millions of voters in the U.S. who strongly support Trump need him to remain that disruptive force against both major political parties and the entrenched elite establishment. Power centers, they believe, never have had their best interests at heart.

As the election approaches, our nation is in a precarious and volatile position. Millions of Americans seem to be on the edge of despair - whether from the destructive fallout from the pandemic, its politicization, the ugly polarization of our politics or the pockets of anarchy.

The killing of George Floyd in Minneapolis was barbaric, and those who rose up in protest were right to do so; their voices need to be heard. But violence in the streets, destruction of property and calls to "defund the police" are deeply worrisome to many Americans. Such anarchy goes too far even for some Democrats, liberals and minority communities. No one wants violence in their neighborhood, town or city, especially Americans who may be struggling to survive.

Against this backdrop, voters will be asked to choose between our disruptive president or tentative former Vice President Joe Biden. I wonder if Democrats privately have confidence in the polls showing Biden leading Trump - or confidence in Biden himself.

But if the storms continue to rage, I suspect enough voters - frightened by the anarchy and nervous about the reversal of course sought by some on the left - will choose to ride it out with Trump until 2024. Then, they'll take a deep breath, collect their thoughts and elect America's first female president.

Douglas MacKinnon was a writer in the White House for Presidents Ronald Reagan and George H.W. Bush, and former special assistant for policy and communication at the Pentagon during the last three years of the Bush administration. He is the author of: "The Dawn of a Nazi Moon: Book One."

The rest is here:

Prepare for four more years of the most disruptive president ever - MSN Money

The X-Men’s Most Unstable Team Is Killing Each Other – Screen Rant

Posted on by

The X-Men started the Hellions hoping it would be a superhero therapy group... but therapy doesn't usually involve mutant guns and chest blasts.

Spoilers for Hellions #2!

The X-Men have been feeling experimental since the start of the Dawn of X relaunch, and their latest attempt at making the lives of mutants better is not going well. The ruling body of the mutant nation Krakoa, the Quiet Council, put together a team of unpredictable, antisocial, even villainous mutants, then tasked them with performing missions that the Council felt would be cathartic and productive. They called that team the Hellions. InHellions #2, the therapeutic superhero squad takes on their first mission... to zero success and lots of violence between teammates.

Hellionsis written by Zeb Wells, illustrated by Stephen Segovia, and colored by David Curiel. The team roster mixes popular X-Men heroes with classic and obscure villains, all under the banner of the new mutant cause of Krakoa and its belief that even the team's worst villainscan find clemency there. The current roster includes Cyclops' brother Havok, psychic ninja Psylocke, feral fighter Wild Child, indoctrinated soldier Orphan-Maker and his protectivecyborg Nanny, emotional manipulator Empath, and techno-shapeshifter Greycrow, with the supervision of mad geneticist Mister Sinister.

Related: X-MEN Theory: Mystique Is X of Swords' Secret Villain

In Hellions #2, the teamsets out to destroy an old lab of Sinisters located beneath a now-abandoned orphanage that Sinister once used as a cover to obtain experimental subjects. Much of the team has ties to Sinister and his baby-snatching operation, and tensions are immediately high. Wild Child attacks a police officer with a K-9 companion in an instinctive effort to become the pack leader.Havok, who grew up there, insists he doesn't belong with the traumatized crew, but Psylocke senses his anxiety is loudest of all since he grew up there under Sinisters' testing schedule.

When Empath decides to blow off steam by nudging Nanny into a frenzy of protective worry, she latches onto Greycrow as if he's a waywardchild. Greycrow doesn't find it funny; he shoots Empath in the head. Since the X-Men have effectively conquered death, this is a matter of paperwork rather than a permanent loss. But stakes get higher the further they delve into the lab, and the team doesn't get any more cohesive.

The real violence begins when the team discovers that diabolical witch Madelyne Pryor has taken up residence in the lab and has been growing half-mindless mutant soldiers from Sinister's leftover, half-fried genetic samples. The enemy mutants may not be highly skilledcombatants, but Madelyne sends each one to fight a Hellion they're perfectly suited to disable. While the others fall, Pryor approaches Havok personally and reminds him of their past romantic history, which leaves him mesmerized enough to leave with her. As her zombifiedclones drag the dead and incapacitatedHellions away, the only two who remain are Psylocke and Wild Child... who sees that the ninja pack leader is wounded and weak, and goes in for the kill.

Hellions is only two issues in and the kinks have clearly yet to be worked out of this roster. Still, since most of the roster is dead, MIA, or trying to kill each other, it might be time to have a long talk between Xavier, Sinister, and--if he ever returns--Havok about the viabilityof this shooting-and-stabbing-based therapy program. Have theQuiet Council given any thought to art therapy? Role-playing? A villains-only dance studio?

Hellions #2is available now from Marvel Comics.

More:The X-Men Typo That Turned Cyclops Into A 'Furry'

Batman Will Finally Face His FIRST Rival, Ghost-Maker

Sean Finley is a comics news writer for ScreenRant. Mutated as a child by a radioactive copy of Amazing Fantasy #15, he now contributes articles, reviews, and short fiction to local and online outlets using a variety of thematic personas. When he isn't writing, he's the forever DM for his local D&D group, where everything is made up and the points don't matter. You can reach him at wseanfinley (at) gmail.com.

Link:

The X-Men's Most Unstable Team Is Killing Each Other - Screen Rant

Massive Growth in Animal Stem Cell Therapy Market Breaking new grounds and touch new level in Upcoming Year by VETSTEM BIOPHARMA, MediVet Biologic,…

Posted on by

Animal Stem Cell Therapy Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Animal Stem Cell Therapy Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Get the PDF Sample Copy of This Report:

https://www.a2zmarketresearch.com/sample?reportId=134420

Key Players Profiled in This Report:

VETSTEM BIOPHARMA, MediVet Biologic, J-ARM, Celavet, Magellan Stem Cells, U.S. Stem Cell, Cells Power Japan, ANIMAL CELL THERAPIES, Animal Care Stem, Cell Therapy Sciences, VetCell Therapeutics, Animacel, Aratana Therapeutics

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Animal Stem Cell Therapy market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Animal Stem Cell Therapy markets trajectory between forecast periods.

Get 20% Discount on this Premium Report at:

https://www.a2zmarketresearch.com/discount?reportId=134420

Reasons for buying this report:

Table of Contents:

Global Animal Stem Cell Therapy Market Research Report

Chapter 1 Animal Stem Cell Therapy Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Animal Stem Cell Therapy Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=134420

Go here to read the rest:

Massive Growth in Animal Stem Cell Therapy Market Breaking new grounds and touch new level in Upcoming Year by VETSTEM BIOPHARMA, MediVet Biologic,...

Stem Cell Therapy for Diabetes and Related Conditions Market analysis with Leading Key Players and Regional Analysis 2026 – CueReport

Posted on by

The Global Stem Cell Therapy for Diabetes and Related Conditions market report offers key information about the industry, helpful and important facts and figures, expert opinions, and the latest developments across the world. The research report represents a comprehensive presumption of the market and encloses imperative future estimations, industry-authenticated figures, and facts of the global market. It predicts inclinations and augmentation statistics with emphasis on abilities & technologies, markets & industries along with the variable market trends. The Stem Cell Therapy for Diabetes and Related Conditions market report analyses and notifies the industry statistics at the global as well as regional and country levels to acquire a thorough perspective of the entire Stem Cell Therapy for Diabetes and Related Conditions market.

The Stem Cell Therapy for Diabetes and Related Conditions market report intends to offer significant information of this business space while elaborating on the key global trends. The document emphasizes on the growth opportunities as well as the drivers that will influence the profitability graph of this business vertical over the estimated timeframe. It also measures the challenges & restraints that may inhibit the expansion of the market.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/25032

The research repot delivers a comparative statement regarding the existing and predicted market scenario to derive the growth rate of this industry vertical over the study duration. Additionally, it measures the effect of COVID-19 outbreak on the regional as well as overall market to denote the methodologies that can help in decision making.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/25032

Major details from Table of Contents:

Product landscape

Application scope

Regional Analysis

Competitive arena

In short, the Stem Cell Therapy for Diabetes and Related Conditions market provides a granular assessment through numerous segmentations, while evaluating the other aspects including sales channel and supply chain processes which consist of downstream buyers, upstream suppliers, and distributors of this business space.

Key Answers Captured in Study Objectives are

Request Customization on This Report @ https://www.cuereport.com/request-for-customization/25032

Continued here:

Stem Cell Therapy for Diabetes and Related Conditions Market analysis with Leading Key Players and Regional Analysis 2026 - CueReport

COVID-19 Fibroblast Based Cell Therapy Candidate Shown to Reduce Lung Scarring in Aggressive Animal Model – PRNewswire

Posted on by

HOUSTON, July 21, 2020 /PRNewswire/ --FibroGenesis announced today new data supporting use of its PneumoBlast product in the battle against COVID-19.Using the widely accepted bleomycin model of lung scarring (fibrosis), Company scientists have demonstrated the administration and use of PneumoBlast induced a 51% reduction of lung fibrosis,which was statistically significant (p < .005). Importantly, when PneumoBlast was compared head to head with bone marrow derived mesenchymal stem cells (BMSCs) for COVID-19, PneumoBlast was 221% more effective. In producing the potent anti-inflammatory protein interleukin 1 receptor antagonist, which is believed to be the mechanism of scar tissue prevention by BMSC therapies currently in development, PneumoBlast was 192% more effective than BMSCs which was again, statistically significant(p < .005).

During an interview with Healthline.com, Dr. Lori Shah, transplant pulmonologist at New York-Presbyterian/Columbia University Irving Medical Center, stated "Holes in the lungs likely refers to an entity that has been dubbed 'post-COVID fibrosis,' otherwise known as post-ARDS [acute respiratory distress syndrome] fibrosis, which is irreversible and can result in severe functional limitations from patients, such as cough, shortness of breath, and need for oxygen." It has been reported that pulmonary fibrosis due to COVID-19 is occurring in increasing numbers of patients in their 20s and 30s.

"COVID-19 represents a new clinical entity which not only causes death through lung inflammation, but in some patients causes permanent lung injury through stimulation of scarring," said Tom Ichim, Ph.D., Chief Scientific Officer of FibroGenesis. "The prospects that our cell therapy approach not only possesses therapeutic effects on animal models of the acute stage of COVID-19, but also benefits the long-term pathology, has our research team extremely excited."

"As the scientific and medical community is discovering more about the biological and medical consequences of the COVID-19 infection, FibroGenesis is eager to contribute to the therapeutic cure options currently being created to fight this global war against an invisible enemy," commented Pete O'Heeron, President/CEO of FibroGenesis. "While we are excited about potential vaccines in the pipeline, the fact remains that there are 3.8 million confirmed cases of COVID-19 in the U.S. and we do not know what the long-term outcomes for these patients will be. To our knowledge, we are the only cell therapy company which is creating a therapy to resolve the initial pathology of infection and also proactively tackling its long-term consequences."

About FibroGenesis

Based in Houston, Texas, FibroGenesis, is a regenerative medicine company developing an innovative solution for chronic disease treatment using human dermal fibroblasts. Currently, FibroGenesis holds 235+ U.S. and international issued patents/patents pending across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, Parkinson's, Chronic Traumatic Encephalopathy, Cancer, Diabetes, Liver Failure, Colitis and Heart Failure. Funded entirely by angel investors, FibroGenesis represents the next generation of medical advancement in cell therapy.

Visit http://www.Fibro-Genesis.com.

SOURCE FibroGenesis

http://www.Fibro-Genesis.com

Excerpt from:

COVID-19 Fibroblast Based Cell Therapy Candidate Shown to Reduce Lung Scarring in Aggressive Animal Model - PRNewswire

Cell Therapy Market Analysis Of Global Trends, Demand And Competition 2020-2028 – Owned

Posted on by

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Cell Therapy market.

Trusted Business Insights presents an updated and Latest Study on Cell Therapy Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Cell Therapy market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Cell Therapy Market

The global cell therapy market size was valued at USD 5.8 billion in 2019 and is projected to witness a CAGR of 5.4% during the forecast period. The development of precision medicine and advancements in Advanced Therapies Medicinal Products (ATMPS) in context to their efficiency and manufacturing are expected to be the major drivers for the market. In addition, automation in adult stem cell and cord blood processing and storage are the key technological advancements that have supported the growth of the market for cell therapy.The investment in technological advancements for decentralizing manufacturing of this therapy is anticipated to significantly benefit the market. Miltenyi Biotec is one of the companies that has contributed to the decentralization in manufacturing through its CliniMACS Prodigy device. The device is an all-in-one automated manufacturing system that exhibits the capability of manufacturing various cell types.

An increase in financing and investments in the space to support the launch of new companies is expected to boost the organic revenue growth in the market for cell therapy. For instance, in July 2019, Bayer invested USD 215 million for the launch of Century Therapeutics, a U.S.-based biotechnology startup that aimed at developing therapies for solid tumors and blood cancer. Funding was further increased to USD 250 billion by a USD 35 million contribution from Versant Ventures and Fujifilm Cellular Dynamics.The biomanufacturing companies are working in collaboration with customers and other stakeholders to enhance the clinical development and commercial manufacturing of these therapies. Biomanufacturers and OEMs such as GE healthcare are providing end-to-end flexible technology solutions to accelerate the rapid launch of therapies in the market for cell therapy.The expanding stem cells arena has also triggered the entry of new players in the market for cell therapy. Celularity, Century Therapeutics, Rubius Therapeutics, ViaCyte, Fate Therapeutics, ReNeuron, Magenta Therapeutics, Frequency Therapeutics, Promethera Biosciences, and Cellular Dynamics are some startups that have begun their business in this arena lately.Use-type InsightsThe clinical-use segment is expected to grow lucratively during the forecast period owing to the expanding pipeline for therapies. The number of cancer cellular therapies in the pipeline rose from 753 in 2018 to 1,011 in 2019, as per Cancer Research Institute (CRI). The major application of stem cell treatment is hematopoietic stem cell transplantation for the treatment of the immune system and blood disorders for cancer patients.In Europe, blood stem cells are used for the treatment of more than 26,000 patients each year. These factors have driven the revenue for malignancies and autoimmune disorders segment. Currently, most of the stem cells used are derived from bone marrow, blood, and umbilical cord resulting in the larger revenue share in this segment.On the other hand, cell lines, such as Induced Pluripotent Stem Cells (iPSC) and human Embryonic Stem Cells (hESC) are recognized to possess high growth potential. As a result, a several research entities and companies are making significant investments in R&D pertaining to iPSC- and hESC-derived products.TherapyType Insights of Cell Therapy Market

An inclination of physicians towards therapeutic use of autologous and allogeneic cord blood coupled with rising awareness about the use of cord cells and tissues across various therapeutic areas is driving revenue generation. Currently, the allogeneic therapies segment accounted for the largest share in 2019 in the cell therapy market. The presence of a substantial number of approved products for clinical use has led to the large revenue share of this segment.

Furthermore, the practice of autologous tissue transplantation is restricted by the limited availability of healthy tissue in the patient. Moreover, this type of tissue transplantation is not recommended for young patients wherein tissues are in the growth and development phase. Allogeneic tissue transplantation has effectively addressed the above-mentioned challenges associated with the use of autologous transplantation.However, autologous therapies are growing at the fastest growth rate owing to various advantages over allogeneic therapies, which are expected to boost adoption in this segment. Various advantages include easy availability, no need for HLA-matched donor identification, lower risk of life-threatening complications, a rare occurrence of graft failure, and low mortality rate.

Regional Insights of Cell Therapy Market

The presence of leading universities such as the Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, and Yale Stem Cell Center that support research activities in U.S. is one of the key factor driving the market for cell therapy in North America. Moreover, strong regulatory and financing support from the federal bodies for expansion of this arena in U.S. as well as Canada is driving the market.In Asia Pacific, the market is anticipated to emerge as a lucrative source of revenue owing to the availability of therapies at lower prices coupled with growing awareness among the healthcare entities and patients pertaining the potential of these therapies in chronic disease management. Japan is leading the Asian market for cell therapy, which can be attributed to its fast growth as a hub for research on regenerative medicine.Moreover, the Japan government has recognized regenerative medicine and cell therapy as a key contributor to the countrys economic growth. This has positively influenced the attention of global players towards the Asian market, thereby driving marketing operations in the region.

Market Share Insights of Cell Therapy Market

Some key companies operating in this market for cell therapy are Fibrocell Science, Inc.; JCR Pharmaceuticals Co. Ltd.; Kolon TissueGene, Inc.; PHARMICELL Co., Ltd.; Osiris Therapeutics, Inc.; MEDIPOST; Cells for Cells; NuVasive, Inc.; Stemedica Cell Technologies, Inc.; Vericel Corporation; and ANTEROGEN.CO.,LTD. These companies are collaborating with the blood centers and plasma collection centers in order to obtain cells for use in therapeutics development.Several companies have marked their presence in the market by acquiring small and emerging therapy developers. For instance, in August 2019, Bayer acquired BlueRock Therapeutics to establish its position in the market for cell therapy. BlueRock Therapeutics is a U.S. company that relies on a proprietary induced pluripotent stem cell (iPSC) platform for cell therapy development.Several companies are making an entry in the space through the Contract Development and Manufacturing Organization (CDMO) business model. For example, in April 2019, Hitachi Chemical Co. Ltd. acquired apceth Biopharma GmbH to expand its global footprint in the CDMO market for cell and gene therapy manufacturing.

Segmentations, Sub Segmentations, CAGR, & High-Level Analysis overview of Cell Therapy Market Research ReportThis report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2019 to 2030. For the purpose of this study, this market research report has segmented the global cell therapy market on the basis of use-type, therapy-type, and region:

Use-Type Outlook (Revenue, USD Million, 2019 2030)

Clinical-use

By Therapeutic Area

Malignancies

Musculoskeletal Disorders

Autoimmune Disorders

Dermatology

Others

By Cell Type

Stem Cell Therapies

BM, Blood, & Umbilical Cord-derived Stem Cells

Adipose derived cells

Others

Non-stem Cell Therapies

Research-use

Therapy Type Outlook (Revenue, USD Million, 2019 2030)

Allogeneic Therapies

Autologous Therapies

Quick Read Table of Contents of this Report @ Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

See the original post here:

Cell Therapy Market Analysis Of Global Trends, Demand And Competition 2020-2028 - Owned

Two Immunotherapies Converted Into Single Therapy for Certain Blood Cancers – Technology Networks

Posted on by

Some of the most promising advances in cancer treatment have centered on immunotherapies that rev up a patients immune system to attack cancer. But immunotherapies dont work in all patients, and researchers have been searching for ways to increase their effectiveness.

Now, researchers at Washington University School of Medicine in St. Louis have combined two immunotherapy strategies into a single therapy and found, in studies in human cells and in mice, that the two together are more effective than either alone in treating certain blood cancers, such as leukemia. Evidence also suggests that the new approach could be safer than one of the most recent cellular immunotherapies to be approved by the FDA, called CAR-T cell therapy, in which the immune systems T cells are engineered to target tumor cells. Cell-based immunotherapies are most commonly used against blood cancers but can be harnessed against some solid tumors as well, such as prostate and lung tumors and melanoma.

The study appears online in the journal Blood.

In the new research, the scientists have harnessed the technology used to engineer CAR-T cells and, instead of modifying specialized immune cells called T cells, they have used similar technology to alter different immune cells called natural killer (NK) cells. The resulting immunotherapy combines the benefits of both strategies and may reduce the side effects that are sometimes seen in CAR-T cell therapy. In some patients, for example, CAR-T cell therapy causes a cytokine storm, a life-threatening overreaction of the immune system.

Immunotherapies show great promise for cancer therapy, but we need to make them more effective and more safe for more patients, said co-senior authorTodd A. Fehniger, MD, PhD, a professor of medicine. This combined approach builds on the treatment strategy that we developed for leukemia patients using natural killer cells. We can supercharge natural killer cells to enhance their ability to attack cancer cells. And at the same time, we can use the genetic engineering approaches of CAR cell therapy to direct the natural killer cells to a tumor target that would normally be overlooked by NK cells. It fundamentally changes the types of cancer that NK cells could be used to treat, both additional blood cancers and potentially solid tumors as well.

In past work, Fehniger and his colleagues showed that they could collect a patients own NK cells, expose the cells to a specific recipe of chemical signals that prime the cells to attack tumors, and then return the primed cells to patients for therapy. This chemical exposure is a sort of basic training for the cells, according to the investigators, preparing the NK cells to fight the cancer. When the cells are then returned to the body, they remember their training, so to speak, and are more effective at targeting the tumor cells. Because their training has given the NK cells a memory of what to do when they encounter tumor cells, the researchers dubbed them memory-like NK cells.

In small clinical trials conducted atSiteman Cancer Centerat Barnes-Jewish Hospital and Washington University School of Medicine, such cells were effective in putting some patients with leukemia into a lasting remission, but they didnt work for everyone. Some tumor cells still evaded the memory-like NK cells, despite the cells basic training. To help the cells find the tumor cells, so their basic training can kick in and kill the correct target, the researchers modified the memory-like NK cells with the same CAR (chimeric antigen receptor) molecule that is typically used to target T cells to tumor cells. The CAR molecule is flexible and can be modified to direct the cells to different tumor types, depending on the proteins on the surfaces of the cancer cells.

The resulting hybrid cells were more effective in treating mice with leukemia than memory-like NK cells alone, leading to longer survival for mice treated with CAR memory-like NK cells. The researchers also found the therapy to be effective despite the fact that the mice were given relatively low doses of the cells.

One aspect of this study I find most exciting is how nicely these hybrid NK cells expand in the mice to respond to their tumors, said co-senior authorMelissa Berrien-Elliott, PhD, an instructor in medicine. We can provide a tiny dose and see an incredible amount of tumor control. To me, this highlights the potency of these cells, as well as their potential to expand once in the body, which is critical for translating these findings to the clinic.

Fehniger also pointed out that an advantage of NK cells in general and for biological reasons that the scientists are still working to understand NK cells dont trigger a dangerous immune response or the long-term side effects that T-cell therapy can cause in attacking the patients healthy tissues, a condition called graft-versus-host disease.

In all of the clinical trials exploring any type of NK cells, we dont see the troublesome side effects of cytokine release syndrome or neurotoxicity that we see with CAR-T cells that can profoundly affect patients, Fehniger said. These side effects can be life-threatening and require intensive care. Were still working to understand how NK cells are different. But if you can get the benefits of CAR-T cells with few if any of the side effects, thats a reasonable line of research to pursue. Another benefit of this safer therapy is the potential to give these cells to patients at an earlier stage in their disease, rather than using them as a last resort.

Other groups have developed CAR-NK cells, but a major difference is that other groups NK cells came from donated cord blood or induced stem cells, rather than adult donors or the patients themselves.

The other groups have artificially differentiated stem cells into something that resembles an NK cell, Fehniger said. With that strategy, theres no guarantee that those cells will have all the properties of typical mature NK cells. In contrast, were starting with adult NK cells, so were more confident that they will have all the inherent properties and behavior of adult NK cells, which we have already shown to be effective in certain types of cancer patients, especially those with leukemia. Inducing memory properties adds to their persistence and effectiveness against many cancer types.

Over the next several years, we would like to be able to scale up this process to produce enough cells for a first-in-human clinical trial, and investigate their effectiveness in different types of human blood cancers, he said.

Reference: Gang, et al. (2020). CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. Blood. DOI: https://doi.org/10.1182/blood.2020006619

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

More:

Two Immunotherapies Converted Into Single Therapy for Certain Blood Cancers - Technology Networks

Researchers ID new target in drive to improve immunotherapy for cancer – UCLA Newsroom

Posted on by

FINDINGS

Researchers at the UCLA Jonsson Comprehensive Cancer Center and UCLA School of Dentistryhave identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma, the most common type of head and neck cancer.

A study in mice found that using an anti-PD1 immunotherapy drug in combination with PTC209, an inhibitor that targets the protein BMI1, successfully stopped the growth and spread of the cancer, prevented reoccurrences and eliminated cancer stem cells. This is the first preclinical study to provide evidence that targeting BMI1 proteins enhances immunotherapy and eliminates cancer stem cells by activating antitumor immunity.

BACKGROUND

Immunotherapies using PD1 blockade have transformed the way people with difficult cancers are treated. Currently, PD1 blockade combined with chemotherapy is approved for recurrent or metastatic head and neck cancer, giving people whose disease would have otherwise been seen as a death sentence another option. However, response rates are not very high and response duration is relatively short, indicating that this type of cancer might be resistant to PD1 blockade.

To help overcome immunotherapy resistance, UCLA researchers have been studying the role of cancer stem cells and the protein BMI1. Growing evidence suggests cancer stem cells might be responsible for such resistance, as well as for relapse or reoccurrence, and BMI1, which functions in several cancers, including head and neck, has been found to control cancer stem cells self-renewal. Targeting cancer stem cells may be critical for improving the efficacy of immunotherapy and preventing tumor relapse.

METHOD

The team used a mouse model of head and neck squamous cell carcinoma that fully mimicked human cancer development and metastasis, allowing them to perform lineage tracing of BMI1-positive cancer stem cells in an undisturbed tumor immune microenvironment. They then tested whether BMI1 cancer stem cells could be eradicated by PD1 blockadebased combination therapy using both pharmacological and genetic inhibition of BMI1. They found that inhibiting BMI1 not only helped eliminate the BMI1 cancer stem cells but also enhanced PD1 blockade by activating tumor cellintrinsic immunity, which inhibited metastatic tumor growth and prevented tumor relapse.

IMPACT

Many people with advanced head and neck cancers who are treated with PD1 blockade and chemotherapy eventually see their cancer return and become resistant to the therapy. This preclinical study provides an important foundation for developing a new PD1 blockadebased combination therapy with BMI1 inhibitors that have the potential to help overcome resistance to the immunotherapy.

AUTHORS

The senior author is Dr. Cun-Yu Wang, professor and chair of oral biology at the UCLA School of Dentistry and a member of the UCLAs Jonsson Comprehensive Cancer Center, Samueli School of Engineering and Broad Stem Cell Research Center. The lead author is Lingfei Jia, an assistant project scientist in oral biology at the School of Dentistry and Jonsson Cancer Center. Wuchang Zhang, an assistant project scientist in oral biology, is also an author.

JOURNAL

The study ispublished onlinein the journal Cell Stem Cell.

FUNDING

The work was supported by grants from the National Institute of Dental and Craniofacial Research, part of the National Institutes of Health.

See original here:

Researchers ID new target in drive to improve immunotherapy for cancer - UCLA Newsroom

Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy – DocWire News

Posted on by

This article was originally published here

Stem Cell Rev Rep. 2020 Jul 21. doi: 10.1007/s12015-020-10004-x. Online ahead of print.

ABSTRACT

Nearly 500000 fatalities due to COVID-19 have been reported globally and the death toll is still rising. Most deaths are due to acute respiratory distress syndrome (ARDS), as a result of an excessive immune response and a cytokine storm elicited by severe SARS-CoV-2 lung infection, rather than by a direct cytopathic effect of the virus. In the most severe forms of the disease therapies should aim primarily at dampening the uncontrolled inflammatory/immune response responsible for most fatalities. Pharmacological agents antiviral and anti-inflammatory molecules have not been able so far to achieve compelling results for the control of severe COVID-19 pneumonia. Cells derived from the placenta and/or fetal membranes, in particular amniotic epithelial cells (AEC) and decidual stromal cells (DSC), have established, well-characterized, potent anti-inflammatory and immune-modulatory properties that make them attractive candidates for a cell-based therapy of COVID19 pneumonia. Placenta-derived cells are easy to procure from a perennial source and pose minimal ethical issues for their utilization. In view of the existing clinical evidence for the innocuousness and efficiency of systemic administration of DSCs or AECs in similar conditions, we advocate for the initiation of clinical trials using this strategy in the treatment of severe COVID-19 disease.

PMID:32696426 | DOI:10.1007/s12015-020-10004-x

View original post here:

Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy - DocWire News

Trending News on Targeted Oncology, Week of July 24, 2020 – Targeted Oncology

Posted on by

In oncology news this week, the FDA accepted a supplemental New Drug Application for selinexor(Xpovio) as treatment of patients with relapsed or refractory multiple myeloma who had received at least 1 prior line of therapy. Meanwhile, theFDA granted clearance for the cancer drug abivertinib to be investigated in a phase 2 study as treatment of hospitalized patients with coronavirus disease 2019 (COVID-19).

This week Targeted Oncology hosted a tweet chat with Alexander N. Shoushtari, MD, of Memorial Sloan Kettering Cancer Center, to discussion the case of a 52-year-old woman withBRAF-mutant metastatic melanoma. Following the tweet chat, Shoushtari continued the discussion in an interview.

Sorafenib Maintenance May Prevent Recurrence After Transplant in FLT3-ITD+ AML

The risk of relapse or death was reduced by 61% with the use of sorafenib maintenance therapy compared with placebo following allogeneic hematopoietic stem cell transplantation in patients withFLT3-ITDpositive acute myeloid leukemia, according to the results of the phase 2 SORMAIN trial.

Ruxolitinib Reduces Spleen Size in Patients With Myelofibrosis and Low-Platelet Counts

Ruxolitinib, the JAK1/2 inhibitor, induced significant spleen responses in patients with myelofibrosis, both with general disease and in patients with low platelet counts, according to results from the phase 3b JUMP study.

Pivotal Phase 3 Trial Initiated to Study Promising Cabozantinib/Atezolizumab Combo in Advanced RCC

A pivotal phase 3 trial has been initiated to explore the combination of cabozantinib and atezolizumab for the treatment of patients with inoperable, locally advanced or metastatic renal cell carcinoma who progressed during or after treatment with an immune checkpoint inhibitor immediately following initial therapy.

CLR 131 Induces Encouraging Responses in Relapsed/Refractory LPL and WM

CLR 131 induced an objective response rate of 100% as treatment of patients with relapsed/refractory lymphoplasmacytic lymphoma and Waldenstrms macroglobulinemia in the ongoing phase 2 CLOVER-1 study.

Avelumab Plus TG4001 Shows Promising Efficacy in HPV16-Positive Metastatic Cancers

Avelumab in combination with a novel HPV16-targeted vaccine, demonstrated clinical activity as treatment of patients with HPV16-positive recurrent and/or metastatic malignancies, a phase 1b/2 clinical trial showed.

A 79-Year-Old Man With Relapsed Chronic Lymphocytic Leukemia

Jeff Sharman, MD, reviews a case of a 79-year-old man with relapsed chronic lymphocytic leukemia in this episode of Targeted Oncology Case Based Peer Perspectives series.

Analyzing the Importance of Biomarker Testing and MSI Status in mCRC

Heinz-Josef Lenz, MD, discusses the significance of conducting biomarker testing in patients with metastatic colorectal cancer in accordance with the results of the phase 2 CheckMate 142 trial.

Limited Toxicity Seen With Leronlimab in Mild to Moderate COVID-19

Treatment with leronlimab in patients with mild to moderate symptoms of respiratory illness from COVID-19 caused fewer serious adverse events when compared with placebo, according to safety results from a phase 2 clinical trial.

Study Shows Disparities, Effects of Treatment for Patients With Cancer and COVID-19

Data from a treatment utilization study revealed racial disparities in treatments for COVID-19 as well as the effects and clinical outcomes of treatments such as remdesivir and dexamethasone in patients with cancer who were diagnosed with COVID-19.

Go here to see the original:

Trending News on Targeted Oncology, Week of July 24, 2020 - Targeted Oncology

The global cell expansion market size is estimated to be USD 14.9 billion in 2020 and projected to reach USD 30.1 billion by 2025, at a CAGR of 15.1%…

Posted on by

NEW YORK, July 22, 2020 /PRNewswire/ --

Read the full report: https://www.reportlinker.com/p05773305/?utm_source=PRN

The global cell expansion market size is estimated to be USD 14.9 billion in 2020 and projected to reach USD 30.1 billion by 2025, at a CAGR of 15.1%. Growth in this market is largely driven by the increasing incidence of chronic diseases, government investments for cell-based research, growing focus on personalized medicine, increasing focus on R&D for cell-based therapies, and increasing GMP certifications for cell therapy production facilities. On the other hand, ethical concerns regarding research in cell biology are expected to limit market growth to a certain extent in the coming years.

By instruments type, the cell expansion supporting equipment accounted for the fasted growing product segment of the cell expansion marketThe instruments segment includes cell expansion supporting equipment, bioreactors, and automated cell expansion systems.The cell expansion supporting equipment market includes flow cytometers, cell counters and hemocytometers, centrifuges, and other supporting equipment.

They are used in cell culture processes for isolating, culturing, scaling-up, and extracting biological products. These instruments are essential in laboratories and institutes for conducting research and analyzing the cell structure and function for cell therapy research. By cell type, the human cells segment accounted for the largest share of the cell expansion market

Based on cell type, the cell expansion market is segmented into human cells and animal cells.The human cells segment includes stem cells and differentiated cells.

The stem cells segment is further classified into adult stem cells, ESCs, and iPSCs. The human cells segment accounted for the larger share of the cell expansion market majorly due to the increasing investments by public and private organizations for research on human cells, growing application areas of human stem cells, and the growing incidence of diseases such as cancer.

Asia Pacific: The fastest-growing region in the cell expansion market.The Asia Pacific market is projected to grow at the highest CAGR during the forecast period, mainly due to the increasing focus of players on emerging Asian markets, increasing incidence of chronic and infectious diseases, rising geriatric population, and government initiatives for infrastructural improvements of healthcare facilities are driving the growth of the cell expansion market in this region.

North America: the largest share of the cell expansion marketNorth America accounted for the largest share of the cell expansion market. The large share of this segment can primarily be attributed to the rising incidence of cancer, increasing government funding, rising research activates on stem cell therapies, growing awareness regarding advanced treatment methods, growing geriatric population, and the strong presence of industry players in the region.

Breakdown of primariesThe study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows: By Company Type Tier 1- 70%, Tier 2- 20% and Tier 3 - 10% By Designation C level Executives- 30%, Directors- 20%, Others - 50% By Region North America - 35%, Europe - 24%, APAC 25%, RoW- 16%

The cell expansion market is dominated by a few globally established players such as Thermo Fisher Scientific, Inc. (US), Danaher (US), Becton, Dickinson and Company (US), Lonza (Switzerland), Corning, Inc. (US), Merck KGaA (Germany), Sartorius Stedim Biotech (France), Getinge AB (Sweden) Terumo Corporation (Japan), Miltenyi Biotec (Germany), PromoCell GmbH (Germany), Takara Bio Inc. (Japan), Solida Biotech GmBH (Germany), HiMedia Laboratories (India), Getinge AB, REPROCELL Inc. (Japan), Kohjin-Bio (Japan), Pierre Gurin (France), Cellexus Ltd.(UK), Eppendorf AG (Germany), CellGenix GmbH (Germany), iXCells Biotechnologies (US), Neuromics (US), Celltainer Biotech B.V. (Netherlands), and G&G Technologies (US).

Research Coverage:The report segments the cell expansion market based on region (Asia Pacific, Europe, North America, and RoW), product (consumables and instruments), cell type (human cells and animal cells), application (regenerative medicine and stem cell research, cancer and cell-based research and other applications), and end user (research institutes, biotechnology and biopharmaceutical companies, cell banks, and other end users).The report also provides a comprehensive review of market drivers, restraints, and opportunities in the cell expansion market.

Key Benefits of Buying the Report:The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments.This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies.

The report also helps stakeholders understand the pulse of the cell expansion market and provides them information on key market drivers, restraints, challenges, and opportunities.

Read the full report: https://www.reportlinker.com/p05773305/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: [emailprotected] US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

http://www.reportlinker.com

Read the original here:

The global cell expansion market size is estimated to be USD 14.9 billion in 2020 and projected to reach USD 30.1 billion by 2025, at a CAGR of 15.1%...

Teslas Next Gigafactory Will Be in Texas – Car and Driver

Posted on by

During its second-quarter 2020 earnings call, Tesla CEO Elon Musk announced that Texas will be the location of the company's next Gigafactory. Musk called the location "GigaTexas" and described the plan for it as an ecological paradise with biking and walking trails.

Construction of the factory already started over the past weekend, according to Musk. The location will be where Tesla will build Model 3 and Model Y vehicles bound for the East Coast. The 2000-acre facility will also be home of the Tesla Semi and the upcoming Cybertruck.

For the Fremont, California, factory, that location will continue to build Model S and Model X for worldwide distribution and will likely be the facility that builds the upcoming Tesla Roadster. It'll also be the home of Model 3 and Y vehicles bound for the West Coast.

Musk said that the location near Austin on the Colorado river would be an ecological paradise with walking and biking paths. The location will also be open to the public. During the call Musk said, "Ive never been more optimistic or excited about the future of Tesla."

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

This commenting section is created and maintained by a third party, and imported onto this page. You may be able to find more information on their web site.

Originally posted here:

Teslas Next Gigafactory Will Be in Texas - Car and Driver

Tesla at $300 billion is much smaller company than Apple, Amazon were at that stage, Morgan Stanley says – MarketWatch

Posted on by

Tesla Inc. TSLA, -6.34% is attracting "greater levels of enthusiasm" from investors thanks to its "demonstrated and perceived" technological dominance, analyst Adam Jonas at Morgan Stanley said in a note Tuesday. Jonas compared Tesla at $300 billion valuation, a milestone reached last week, with Apple Inc. AAPL, -0.24% at $300 billion, which the Cupertino, Calif., company crossed in early 2011, and Amazon.com Inc. AMZN, +0.74% at $300 billion, reached in late 2015. Tesla is a "significantly smaller company" than either companies were at the time, and Tesla's market-cap milestone reflects a "significant valuation premium" compared to when Apple and Amazon reached the same market value, he said. Tesla's revenue is less than half Apple's at the time of the $300 billion milestone, and 70% less than Amazon's at Amazon's market value milestone, Jonas said. Some S&P 500 index's SPX, -0.61% market ratios are higher today, which explains some of the valuation premium for Tesla, he said. Tesla is scheduled to report second-quarter results on Wednesday after the bell, with Wall Street consensus calling for a loss. Some investors, however, remain hopeful the Silicon Valley car maker will surprise markets with a GAAP profit and be on its way to eventually join the S&P 500 index.

See the original post:

Tesla at $300 billion is much smaller company than Apple, Amazon were at that stage, Morgan Stanley says - MarketWatch

Global Location-based Virtual Reality Market 2020 to Witness Huge Growth by 2020 | Top Key Players; Oculus VR, HTC Vive Tech, Survios, EXIT Realty,…

Posted on by

The report on the Global Location-based Virtual Reality Market features detailed insights and deep research. The report introduces the important factors which driving the growth of the global Location-based Virtual Reality market, untapped opportunities for the manufacturers, current trends, and developments shaping the global Location-based Virtual Reality market and other factors across various key segments.

In addition, report highlights the market drivers, future opportunities and restraints which impacting the growth of the global Location-based Virtual Reality market. Along with these, report also provides the changing trends which are directly and indirectly influence the market are also analyzed and incorporated in the report to gives the detailed information related to the market which resulting for better decision making.

The study encompasses profiles of major companies operating in the Location-based Virtual Reality Market. Key players profiled in the report includes:Oculus VRHTC Vive TechSurviosEXIT RealtyVOIDSpaceVRZero Latency PTYHologateTyffon

Available Sample Report in PDF Version along with Graphs and Figures@ https://www.innovateinsights.com/report/global-location-based-virtual-reality-market-2020-industry/261865/#requestsample

By the product type, the market is primarily split into: HardwareSoftware

By the end-users/application, this report covers the following segments:VR ArcadesVR Theme ParksVR Cinemas

Market, By regions: North America (U.S., Canada, Mexico) Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS) Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific) Latin America (Brazil, Rest of L.A.) Middle East and Africa (Turkey, GCC, Rest of Middle East)

The Location-based Virtual Reality market report provides the section which highlights country-wise demand for the Location-based Virtual Reality and provides a market outlook. The report also analyses the new technological developments as well as offerings for niche applications in the global Location-based Virtual Reality market. In last section of the report, a competitive landscape has been included to provide audiences with a dashboard view.

In addition, report explores the detailed market share analysis of the Location-based Virtual Reality market by considering the key manufacturers. Detailed profiling of the manufacturers is also included along with their business and growth strategies, key offerings and recent developments in the global Location-based Virtual Reality market.

Do You Have Any Query or Specific Requirement? Ask to Our Industry Expert@ https://www.innovateinsights.com/report/global-location-based-virtual-reality-market-2020-industry/261865/#buyinginquiry

Global Location-based Virtual Reality Market Report: Research Methodology

Market analysis is obtained through in-depth secondary research which is validated and verified by primary interviews. Every primary research is analyzed and average market volume is deduced and reconfirmed prior to incorporating in the report. The price of Location-based Virtual Reality is calculated across all the assessed regions and weighted average price is also considered. The market value of the global Location-based Virtual Reality market is thus calculated from the data deduced from the average selling price and market volume.

For future market growth, forecast of the global Location-based Virtual Reality market, offers the various macroeconomic factors and changing trends have been observed, based on which the future of the market is predicted. Other important factors covered by report includes the size of the current market, inputs from the supply side and the demand side and other dynamics shaping the scenario of the market. Report forecasts are offered in terms of CAGR, while other important criteria such as year-on-year growth and absolute dollar opportunity have also been incorporated giving clear insights and future opportunities.

Impact of Covid-19 in Location-based Virtual Reality Market

The utility-owned segment is mainly being driven by increasing financial incentives and regulatory supports from the governments globally. The current utility-owned Location-based Virtual Reality are affected primarily by the COVID-19 pandemic. Most of the projects in China, the US, Germany, and South Korea are delayed, and the companies are facing short-term operational issues due to supply chain constraints and lack of site access due to the COVID-19 outbreak. Asia-Pacific is anticipated to get highly affected by the spread of the COVID-19 due to the effect of the pandemic in China, Japan, and India. China is the epic center of this lethal disease. China is a major country in terms of the chemical industry.

Access Full Report, here: https://www.innovateinsights.com/report/global-location-based-virtual-reality-market-2020-industry/261865/

View post:

Global Location-based Virtual Reality Market 2020 to Witness Huge Growth by 2020 | Top Key Players; Oculus VR, HTC Vive Tech, Survios, EXIT Realty,...